Back
Ned Davis Research 360 Dyn Allc ETF Vs. Halozyme Therapeutics Industry Stock Comparison
Sell
1
NDAA
Ned Davis Research 360 Dyn Allc ETF
Last Price:
19.71
Seasonality Move:
--
Sell
39
HALO
Halozyme Therapeutics
Last Price:
42.76
Seasonality Move:
17.03%
Sell
1
Ned Davis Research 360 Dyn Allc ETF (NDAA)
is a Sell
Is Ned Davis Research 360 Dyn Allc ETF a Buy, Sell or Hold?
- The current Ned Davis Research 360 Dyn Allc ETF [NDAA] share price is $19.71. The Score for NDAA is 1, which is 98% below its historic median score of 50, and infers higher risk than normal.
- NDAA is currently trading in the 0-10% percentile range relative to its historical Stock Score levels.
- This Score is currently showing an extreme reading that indicates risk could be especially high.
Sell
39
Halozyme Therapeutics (HALO)
is a Sell
Is Halozyme Therapeutics a Buy, Sell or Hold?
- The current Halozyme Therapeutics [HALO] share price is $45.65. The Score for HALO is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
- HALO is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
NDAA Stock Price Chart
What is Ned Davis Research 360 Dyn Allc ETF's stock price today?
-
The Ned Davis Research 360 Dyn Allc ETF share price today is $19.71
The current trend is relatively stagnant and NDAA is experiencing slight buying pressure.
HALO Stock Price Chart
What is Halozyme Therapeutics's stock price today?
-
The Halozyme Therapeutics share price today is $45.65
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and HALO is experiencing selling pressure, which indicates risk of future bearish movement.
NDAA Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 3.58 | Buy |
| Relative Strength Index (14 RSI): | 37.24 | Sell |
| Chaikin Money Flow: | 0 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | ( - ) | Buy |
| Bollinger Bands (100): | ( - ) | Buy |
HALO Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.02 | Sell |
| Relative Strength Index (14 RSI): | 30.2 | Sell |
| Chaikin Money Flow: | -7140517 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (49.94 - 58.56) | Sell |
| Bollinger Bands (100): | (52.16 - 60.38) | Sell |
NDAA Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 20.06 | Sell |
| 20-day SMA: | 19.93 | Sell |
| 50-day SMA: | 0 | Buy |
| 200-day SMA: | 0 | Buy |
| 8-day EMA: | 19.82 | Sell |
| 20-day EMA: | 17.25 | Buy |
| 50-day EMA: | 10.98 | Buy |
| 200-day EMA: | 3.61 | Buy |
HALO Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 57.53 | Sell |
| 20-day SMA: | 54.48 | Sell |
| 50-day SMA: | 56.18 | Sell |
| 200-day SMA: | 48.93 | Sell |
| 8-day EMA: | 55 | Sell |
| 20-day EMA: | 55.41 | Sell |
| 50-day EMA: | 55.64 | Sell |
| 200-day EMA: | 50.73 | Sell |
Ned Davis Research 360 Dyn Allc ETF Earnings Growth & NDAA Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Halozyme Therapeutics Earnings Growth & HALO Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.35 per share, and an increase next year of $0.56 per share.
Ned Davis Research 360 Dyn Allc ETF Technical Analysis
| Nov 4 | Nov 5 | Nov 6 | Nov 7 | Nov 8 | Nov 11 | Nov 12 | Nov 13 | Nov 14 | Nov 15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 04 | 05 | 06 | 07 | 08 | 11 | 12 | 13 | 14 | 15 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Halozyme Therapeutics Technical Analysis
| Nov 4 | Nov 5 | Nov 6 | Nov 7 | Nov 8 | Nov 11 | Nov 12 | Nov 13 | Nov 14 | Nov 15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 04 | 05 | 06 | 07 | 08 | 11 | 12 | 13 | 14 | 15 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||